For patients with PD-L1 tumor expression ≥1%, noninferiority of nivolumab to placebo was not demonstrated for EORTC QLQ-C30 emotional functioning (the lower bound of the 95% confidence interval [CI] for the difference between nivolumab and placebo in LS mean change from baseline [−3.43] exceeded the prespecified noninferiority margin of −3; Supplementary Table 5). Here, CD274 is linked to neoplasm.